Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by ...

DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors ...

DexCom Inc (NASDAQ:DXCM) shares up more than 2% following updated guidelines by the American Diabetes Association (ADA), which now recommend using continuous glucose monitors (CGMs) for some adults ...

Tandem Diabetes Care announced today that t:slim X2 insulin pump users in Canada can now access full compatibility with ...

DexCom, Inc. (DXCM), headquartered in California, is a leading player in the medical devices sector. Valued at a market cap ...

SAN DIEGO, September 18, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third ...

In the assessment of 12-month price targets, analysts unveil insights for DexCom, presenting an average target of $98.44, a ...

In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

The American Diabetes Association has released its annual guidelines and they now include continuous glucose monitor use for non-insulin use, ...

DexCom (NASDAQ:DXCM – Get Free Report) had its target price increased by stock analysts at Canaccord Genuity Group from $89.00 to $99.00 in a research report issued to clients and investors on Monday, ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...